TY - JOUR
T1 - Immunological aspects of approved MS therapeutics
AU - Rommer, Paulus S.
AU - Milo, Ron
AU - Han, May H.
AU - Satyanarayan, Sammita
AU - Sellner, Johann
AU - Hauer, Larissa
AU - Illes, Zsolt
AU - Warnke, Clemens
AU - Laurent, Sarah
AU - Weber, Martin S.
AU - Zhang, Yinan
AU - Stuve, Olaf
N1 - Funding Information:
Conflict of Interest Statement: PR received honoraries from consultancy or lectures from AbbVie, Biogen, Celgene (institutional), Merck, Roche, Sanofi Genzyme, Teva. He served on advisory boards for Biogen, Merck, Roche, Sandoz. PR received research support from Biogen, Merck Serono and Roche. RM received honoraria/consulting fees: Actelion, Bayer Healthcare, Biogen-Idec, Medison, Merck-Serono, Neopharm, Novartis, Roche, Sanofi-Genzyme, Teva, and TG-Therapeutics. He served on advisory boards: Bayer Healthcare, Genzyme, Medison, Merck, Neopharm, Novartis, Roche Teva, and TG-Therapeutics. He received research grants: Bayer Healthcare, Medison, Merck-Serono, Novartis, and Teva. MH is on the steering committee for the Novartis FLUENT study. JS received personal compensation as a speaker or consultant from Bayer, Biogen, Merck, Gerot-Lannach, Roche, Sanofi, and Teva. He is member of advisory boards of Biogen, Merck, Sanofi, Roche, and MedDay. His institution received unrestricted grants from Biogen, Merck, Roche, and Sanofi. ZI has served on scientific advisory board for Biogen, Sanofi-Genzyme, Teva, Roche, Novartis, Merck; has received honoraria for lecturing from Biogen, Merck, Teva, Novartis, Sanofi-Genzyme; research support from Biogen, Sanofi-Genzyme, Merck; and support for congress participation from Biogen, Sanofi-Genzyme, Teva, Roche, Novartis, Merck. CW received speaker honoraria (institutional only) and/or research funding from Biogen, Novartis, Sanofi-Genzyme, and Roche.
Publisher Copyright:
© 2019 Rommer, Milo, Han, Satyanarayan, Sellner, Hauer, Illes, Warnke, Laurent, Weber, Zhang and Stuve.
PY - 2019
Y1 - 2019
N2 - Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading to disability in young adults. The outcome of the disease is unpredictable, and over time, neurological disabilities accumulate. Interferon beta-1b was the first drug to be approved in the 1990s for relapsing-remitting MS to modulate the course of the disease. Over the past two decades, the treatment landscape has changed tremendously. Currently, more than a dozen drugs representing 1 substances with different mechanisms of action have been approved (interferon beta preparations, glatiramer acetate, fingolimod, siponimod, mitoxantrone, teriflunomide, dimethyl fumarate, cladribine, alemtuzumab, ocrelizumab, and natalizumab). Ocrelizumab was the first medication to be approved for primary progressive MS. The objective of this review is to present the modes of action of these drugs and their effects on the immunopathogenesis of MS. Each agent's clinical development and potential side effects are discussed.
AB - Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading to disability in young adults. The outcome of the disease is unpredictable, and over time, neurological disabilities accumulate. Interferon beta-1b was the first drug to be approved in the 1990s for relapsing-remitting MS to modulate the course of the disease. Over the past two decades, the treatment landscape has changed tremendously. Currently, more than a dozen drugs representing 1 substances with different mechanisms of action have been approved (interferon beta preparations, glatiramer acetate, fingolimod, siponimod, mitoxantrone, teriflunomide, dimethyl fumarate, cladribine, alemtuzumab, ocrelizumab, and natalizumab). Ocrelizumab was the first medication to be approved for primary progressive MS. The objective of this review is to present the modes of action of these drugs and their effects on the immunopathogenesis of MS. Each agent's clinical development and potential side effects are discussed.
KW - Immunomodulation
KW - Immunosuppression
KW - Immunotherapeutics
KW - Monoclonal antibodies
KW - Multiple sclerosis
UR - http://www.scopus.com/inward/record.url?scp=85069437101&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069437101&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2019.01564
DO - 10.3389/fimmu.2019.01564
M3 - Review article
C2 - 31354720
AN - SCOPUS:85069437101
VL - 10
JO - Frontiers in Immunology
JF - Frontiers in Immunology
SN - 1664-3224
IS - JULY
M1 - 1564
ER -